EGFR and hepatocellular adenoma: Thus, reduction of proliferative activity of FAH cannot be attributed to this signaling pathway inhibition, as epatocellular neoplasms, such as HCA after 24 months, also reveal upregulation of the EGFR and TGFα after Gefitinib treatment (Figure 3).